An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
Launched by UNIVERSITY OF MICHIGAN · Sep 21, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The IDEA3 trial is studying a special online program designed to help reduce the risk of sexual assault among undergraduate women. This program, called Enhanced Assess, Acknowledge, Act (IDEA3), involves participants attending four three-hour group sessions with a partner, where they will learn about resisting sexual violence. The researchers want to see if this program will lead to fewer instances of sexual assault over the year following the sessions. Participants in a comparison group will only attend a shorter, one-hour workshop on consent.
To be eligible for this trial, you need to be a first- or second-year female-identifying university student aged 17 to 24. You should also be able to attend the scheduled sessions and willing to pair up with another eligible student for the program. If you decide to join, you'll complete surveys before and after the program to help the researchers understand its effectiveness. This trial is currently recruiting participants, and your involvement could play an important role in helping other students stay safe.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1st- and 2nd-year university students at one of the 4 sites
- • female-identifying students
- • students between ages of 17-24
- • able to attend one of the scheduled program groups
- • able and willing to be matched with another eligible student
- Exclusion Criteria:
- • - None
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Guelph, Ontario, Canada
Windsor, Ontario, Canada
Lincoln, Nebraska, United States
Patients applied
Trial Officials
Sarah M Peitzmeier, PhD
Principal Investigator
University of Michigan
Charlene Y Senn, PhD
Principal Investigator
University of Windsor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported